Andrew Racette, DO
Dermatology · Phoenix, AZNPI 1447429097
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (53.8%), consulting fees and travel and lodging — rather than concentrated in one kind of arrangement. 34 manufacturers reported payments, led by Sun Pharmaceutical Industries Inc. at 51.7% of the total. Reporting peaked in 2024 at $8,931 and has fallen 85.6% since, to $1,290 in 2025.
Across 425 payments — averaging $37.07 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sun Pharmaceutical Industries Inc.$8K
- AbbVie$2K
- Amgen$989
- Johnson & Johnson$616
- Lilly USA, LLC$463
- Novartis$460
- plus $3K from 28 others
Across 64 payments — averaging $1341.37 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Incyte Corporation$59K
- Taro Pharmaceuticals USA, Inc.$19K
- Dr.reddy's Laboratories,inc.$5K
- AbbVie$3K
- E.r. Squibb & Sons, L.L.C.$61
What the payments were for
- Consulting fees$6,00038%
- Travel & lodging$1,1017%
- Food & beverage$8,47354%
- Education$1801%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Sun Pharmaceutical Industries Inc. | 36 | $8,146 |
| AbbVie | 109 | $1,958 |
| Amgen | 47 | $989 |
| Johnson & Johnson | 46 | $616 |
| Lilly USA, LLC | 29 | $463 |
| Novartis | 27 | $460 |
| Sanofi | 17 | $438 |
| Regeneron Healthcare Solutions, Inc. | 14 | $424 |
| LEO Pharma Inc. | 9 | $320 |
| Smith+Nephew | 15 | $292 |
| Pfizer | 12 | $246 |
| E.r. Squibb & Sons, L.L.C. | 11 | $228 |
| Organogenesis Inc. | 3 | $207 |
| UCB, Inc. | 11 | $199 |
| Ortho Dermatologics, A Division Of Bausch Health US, LLC | 8 | $115 |
| Organon | 2 | $92 |
| Boehringer Ingelheim | 3 | $84 |
| Bristol Myers Squibb | 4 | $64 |
| Mylan Institutional Inc. | 2 | $53 |
| Genentech USA, Inc. | 2 | $44 |
| Biofrontera Inc. | 2 | $39 |
| Dermira, Inc. | 2 | $38 |
| Incyte Corporation | 2 | $32 |
| Krystal Biotech Inc | 1 | $25 |
| Verrica Pharmaceuticals Inc. | 1 | $25 |
| Biocon Biologics Inc | 1 | $22 |
| Mayne Pharma Commercial LLC | 1 | $21 |
| Strata Skin Sciences, Inc. | 2 | $19 |
| Sanofi-aventis U.S. LLC | 1 | $19 |
| Kyowa Kirin, Inc. | 1 | $17 |
| Integra Lifesciences Corporation | 1 | $17 |
| Merck | 1 | $14 |
| Sandoz | 1 | $14 |
| Oxford Immunotec USA Inc | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ODOMZO$7,276
- ANZUPGO$172
- PURAPLY WOUND MATRIX$165
How this compares
$15,754 in reported general payments places this provider in the 85th percentile of 305 dermatology providers in Arizona.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OdomzoSonidegib Phosphate | 84 | $1,241,525 |
| Dupixent PenDupilumab | 41 | $168,499 |
| OtezlaApremilast | 14 | $69,202 |
| Dupixent SyringeDupilumab | 15 | $56,370 |
| Clobetasol Propionate | 42 | $3,797 |
| Ketoconazole | 26 | $555 |
| Doxycycline Hyclate | 23 | $496 |
| Triamcinolone Acetonide | 17 | $299 |
| Mupirocin | 17 | $153 |
| Prednisone | 14 | $101 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AmgenOtezla | $989 | $69,20214 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 305 dermatology providers in Arizona.
Other dermatology in Phoenix
- Lindsay AckermanPhoenix$1.6M
- Nathalie ZeitouniPhoenix$584K
- Carsten HamannPhoenix$364K
- Michael CrandallPhoenix$153K
- Sadra JazayeriPhoenix$115K
- Cynthia PricePhoenix$76K
- William KoPhoenix$66K
- Dathan HamannPhoenix$56K
- Peter SigalPhoenix$30K
- Xuan NguyenPhoenix$19K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.